Literature DB >> 28257141

Bayesian population finding with biomarkers in a randomized clinical trial.

Satoshi Morita1, Peter Müller2.   

Abstract

The identification of good predictive biomarkers allows investigators to optimize the target population for a new treatment. We propose a novel utility-based Bayesian population finding (BaPoFi) method to analyze data from a randomized clinical trial with the aim of finding a sensitive <span class="Species">patient population. Our approach is based on casting the population finding process as a formal decision problem together with a flexible probability model, Bayesian additive regression trees (BART), to summarize observed data. The proposed method evaluates enhanced treatment effects in <span class="Species">patient subpopulations based on counter-factual modeling of responses to new treatment and control for each patient. In extensive simulation studies, we examine the operating characteristics of the proposed method. We compare with a Bayesian regression-based method that implements shrinkage estimates of subgroup-specific treatment effects. For illustration, we apply the proposed method to data from a randomized clinical trial.
© 2017, The International Biometric Society.

Entities:  

Keywords:  Bayesian additive regression trees; Bayesian decision problem; Biomarkers; Population finding; Randomized clinical trial

Mesh:

Substances:

Year:  2017        PMID: 28257141      PMCID: PMC5582025          DOI: 10.1111/biom.12677

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  16 in total

1.  The mean does not mean as much anymore: finding sub-groups for tailored therapeutics.

Authors:  Stephen J Ruberg; Lei Chen; Yanping Wang
Journal:  Clin Trials       Date:  2010-07-28       Impact factor: 2.486

2.  Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

Authors:  Isamu Okamoto; Hiroshige Yoshioka; Satoshi Morita; Masahiko Ando; Koji Takeda; Takashi Seto; Nobuyuki Yamamoto; Hideo Saka; Kazuhiro Asami; Tomonori Hirashima; Shinzoh Kudoh; Miyako Satouchi; Norihiko Ikeda; Yasuo Iwamoto; Toshiyuki Sawa; Masaki Miyazaki; Kenji Tamura; Takayasu Kurata; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

3.  Bayesian subset analysis.

Authors:  D O Dixon; R Simon
Journal:  Biometrics       Date:  1991-09       Impact factor: 2.571

4.  Subgroup identification from randomized clinical trial data.

Authors:  Jared C Foster; Jeremy M G Taylor; Stephen J Ruberg
Journal:  Stat Med       Date:  2011-08-04       Impact factor: 2.373

5.  A Bayesian subgroup analysis with a zero-enriched Polya Urn scheme.

Authors:  S Sivaganesan; Purushottam W Laud; Peter Müller
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

6.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  Lesley Seymour; S Percy Ivy; Daniel Sargent; David Spriggs; Laurence Baker; Larry Rubinstein; Mark J Ratain; Michael Le Blanc; David Stewart; John Crowley; Susan Groshen; Jeffrey S Humphrey; Pamela West; Donald Berry
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

7.  Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times.

Authors:  Yanxun Xu; Peter Müller; Abdus S Wahed; Peter F Thall
Journal:  J Am Stat Assoc       Date:  2016-10-18       Impact factor: 5.033

Review 8.  Effective incorporation of biomarkers into phase II trials.

Authors:  Lisa M McShane; Sally Hunsberger; Alex A Adjei
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

Authors:  Theodore G Karrison; Michael L Maitland; Walter M Stadler; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

10.  A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).

Authors:  Akira Tsuburaya; Satoshi Morita; Yasuhiro Kodera; Michiya Kobayashi; Kohei Shitara; Kensei Yamaguchi; Takaki Yoshikawa; Kazuhiro Yoshida; Shigefumi Yoshino; Jun-ichi Sakamoto
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

View more
  3 in total

Review 1.  Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.

Authors:  Ciara Nugent; Wentian Guo; Peter Müller; Yuan Ji
Journal:  JCO Precis Oncol       Date:  2019-10-24

2.  Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.

Authors:  Yoon-Koo Kang; Satoshi Morita; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Hiroki Sameshima; Li-Tzong Chen; Narikazu Boku
Journal:  Gastric Cancer       Date:  2021-09-04       Impact factor: 7.370

3.  Aim for Clinical Utility, Not Just Predictive Accuracy.

Authors:  Michael C Sachs; Arvid Sjölander; Erin E Gabriel
Journal:  Epidemiology       Date:  2020-05       Impact factor: 4.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.